What an ID reader looks for
- The mechanism, not just the gene. Each detected gene is labelled with what it does and which agents it defeats — see the resistance gene library.
- Agents spared, not only removed. mecA removes the beta-lactams PBP2a defeats and keeps ceftaroline; tetB / tetM keeps omadacycline and tigecycline.
- Carbapenemase context. KPC is handled differently across the newer beta-lactam / inhibitor combinations; metallo-beta-lactamases spare aztreonam.
- Negatives kept. Every target tested but not detected is listed.
- Colonizers named. When a detected organism is more likely a bystander, the summary says so.
Stewardship
Removing agents the organism is intrinsically resistant to, removing agents not indicated at the site, and preferring oral options where appropriate all push toward narrower, shorter therapy — which is what stewardship programmes ask for.
Browse by panel
Decision support only. Molecular genotype does not replace phenotypic susceptibility testing, culture, or public-health reporting.
Pathogens
Resistance genes
Decision support only. The treating clinician decides. Molecular genotype does not replace phenotypic susceptibility testing, culture, or public-health reporting. Absence of a detected resistance gene does not establish susceptibility. Organism targets vary by panel; CORE-ABR is configured to the assay each laboratory runs.